Mangoceuticals, Inc. (MGRX)

Mangoceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	0.52	0.62	0.73	0.01
Revenue Growth (YoY)	-40.47%	-15.81%	8083.16%	-
Cost of Revenue	0.2	0.24	0.3	0
Gross Profit	0.31	0.38	0.43	0
Selling, General & Admin	13.87	8.35	9.65	2
Depreciation & Amortization Expenses	-	0.72	-	-
Total Operating Expenses	13.87	9.07	9.65	2
Operating Income	-13.56	-7.97	-9.22	-1.99
Interest Expense	-	-0.01	0.01	-0.01
Other Non-Operating Income (Expense)	-	-0.72	-	-
Total Non-Operating Income (Expense)	-	-0.74	0.01	-0.01
Pretax Income	-14.2	-8.71	-9.21	-2
Net Income	-14.2	-8.71	-9.21	-2
Minority Interest in Earnings	-0	-0	-	-
Net Income to Common	-14.2	-8.71	-9.21	-2
Shares Outstanding (Basic)	5	2	1	1
Shares Outstanding (Diluted)	5	2	1	1
Shares Change (YoY)	230.12%	84.23%	49.22%	-
EPS (Basic)	-3.83	-4.84	-8.58	-2.85
EPS (Diluted)	-3.83	-4.84	-8.58	-2.85
Free Cash Flow	-5.83	-4.86	-7	-1.39
Free Cash Flow Per Share	-1.22	-2.46	-6.52	-1.93
Gross Margin	61.00%	61.70%	58.99%	54.26%
Operating Margin	-2627.25%	-1294.42%	-1260.28%	-22279.70%
Profit Margin	-2752.48%	-1413.80%	-1259.40%	-22352.11%
FCF Margin	-1129.13%	-789.74%	-957.07%	-15545.59%
EBITDA	-13.56	-7.24	-9.19	-1.99
EBITDA Margin	-2627.06%	-1175.65%	-1256.88%	-22236.48%
EBIT	-13.56	-7.97	-9.22	-1.99
EBIT Margin	-2627.25%	-1294.42%	-1260.28%	-22279.70%

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q